[
  {
    "ts": null,
    "headline": "Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
    "summary": "WILMINGTON, Del., April 07, 2025--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
    "url": "https://finnhub.io/api/news?id=e35f2173408346f89f1070519caf7e3fbdad895a269ccb89e37dcce017a81ff5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744057800,
      "headline": "Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
      "id": 133752691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., April 07, 2025--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
      "url": "https://finnhub.io/api/news?id=e35f2173408346f89f1070519caf7e3fbdad895a269ccb89e37dcce017a81ff5"
    }
  },
  {
    "ts": null,
    "headline": "Syndax Pharmaceuticals: Down But Not Out",
    "summary": "Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my recommendation for SNDX.",
    "url": "https://finnhub.io/api/news?id=5e2e984882f8d5189cb1b46cec2720a49ca9e3e2cac1350b0e16fff99144f9f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744016920,
      "headline": "Syndax Pharmaceuticals: Down But Not Out",
      "id": 133738249,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my recommendation for SNDX.",
      "url": "https://finnhub.io/api/news?id=5e2e984882f8d5189cb1b46cec2720a49ca9e3e2cac1350b0e16fff99144f9f8"
    }
  },
  {
    "ts": null,
    "headline": "Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)",
    "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst performers in the immuno-oncology industry.",
    "url": "https://finnhub.io/api/news?id=aa55500cedceeea1397051a5084f860bb969b887e0e37091a573a9d0f24b0721",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744016487,
      "headline": "Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)",
      "id": 133738998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst performers in the immuno-oncology industry.",
      "url": "https://finnhub.io/api/news?id=aa55500cedceeea1397051a5084f860bb969b887e0e37091a573a9d0f24b0721"
    }
  }
]